Research Article
Efficacy and Safety of Rivaroxaban versus Warfarin for the Treatment of Acute Pulmonary Embolism: A Real-World Study
Table 4
Safety of patients with expected course of treatment.
| Variable | Group | | Rivaroxaban (86) | Warfarin (42) | | value |
| Reexamination after 1 month | No bleeding | 55 | 40 (46.51%) | 15 (35.71%) | 0.7656 | 0.3816 | Mild bleeding | 54 | 36 (41.86%) | 18 (42.86%) | 0.0066 | 0.9350 | Serve bleeding | 3 | 0 (0%) | 3 (7.14%) | 6.1429 | 0.0132 | Major bleeding | 2 | 0 (0%) | 2 (4.76%) | 4.0952 | 0.0430 | — | 14 | 10 (11.63%) | 4 (9.52%) | | |
| Reexamination after 3 months | No bleeding | 49 | 38 (44.19%) | 11 (26.19%) | 2.3872 | 0.1223 | Mild bleeding | 61 | 40 (46.51%) | 21 (50%) | 0.0721 | 0.7884 | Serve bleeding | 3 | 0 (0%) | 3 (7.14%) | 6.1429 | 0.0132 | Major bleeding | 2 | 0 (0%) | 2 (4.76%) | 4.0952 | 0.0430 | — | 13 | 8 (9.3%) | 5 (11.9%) | | |
| Reexamination after 6 months | No bleeding | 46 | 37 (43.02%) | 9 (21.43%) | 3.6617 | 0.0557 | Mild bleeding | 65 | 41 (47.67%) | 24 (57.14%) | 0.4982 | 0.4803 | Serve bleeding | 4 | 1 (1.16%) | 3 (7.14%) | 3.2292 | 0.0723 | Major bleeding | 3 | 1 (1.16%) | 2 (4.76%) | 1.5596 | 0.2117 | — | 10 | 6 (6.98%) | 4 (9.52%) | | |
|
|